Dynamics of tumour angiogenesis: Effect of razoxane-induced growth rate slowdown

Clinical and Experimental Metastasis

Volumn 20, Issue 2, 2003, Pages 95-102

  Hellmann, K ^a,b  

^a Windleshaw House ^*  (United Kingdom)

^b Windleshaw House   (United Kingdom)

Author keywords

Angiodynamics; Breast cancer; Colorectal; Crohn's disease; Metastasis; Psoriasis; Razoxane; Renal

Indexed keywords

593A; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARMUSTINE; DAUNORUBICIN; DIETHYLSTILBESTROL; DOXORUBICIN; FLUOROURACIL; HADACIDIN; LOMUSTINE; RAZOXANE; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ANGIODYNAMICS; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CARDIOTOXICITY; COLORECTAL CANCER; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; KAPOSI SARCOMA; KIDNEY CANCER; LEUKEMIA; METASTASIS; METASTASIS INHIBITION; MITOSIS RATE; NONHUMAN; PHARMACODYNAMICS; PSORIASIS; QUALITY OF LIFE; REVIEW; SURVIVAL TIME; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RAZOXANE;

EID: 0037247791     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022632413888     Document Type: Review

References (45)

1. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nature Rev Cancer 2002; 2: 727-39.
2. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-6.
3. Salsbury AJ, Burrage K, Hellmann K. Inhibition of metastatic spread by ICRF 159: Selective deletion of a malignant characteristic. BMJ 1970; 4: 344-6.
4. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001; 7: 987-9.
5. Le Serve AW, Hellmann K. Metastases and the normalization of tumour blood vessels by ICRF 159: A new type of drug action. BMJ 1972; 1: 597-601.
6. Hellmann K, Burrage K. Control of malignant metastases by ICRF 159. Nature 1969; 224: 273-5.
7. Willis R. The Spread of Tumours in the Human Body. London: Butterworth 1952; 115.
8. Hellmann K. Serendipity in cancer chemotherapy. New Sci J 1971; 21: 111-3.
9. Salsbury AJ, Burrage K, Hellmann K. Histological analysis of the antimetastatic effect of 1,2-bis(3,5-dioxopiperazine-1-yl)propane. Cancer Res 1974; 34: 843-9.
10. Heston WDW, Kadmon D, Fair WR. Effect of high dose diethyl-stilbestrol and ICRF 159 on the growth and metastases of the R3327 MAT-LyLu prostate-derived tumor. Cancer Lett 1981; 13: 139-45.
11. Pollard M, Burleson GR, Luckert PH. Interference with in vivo growth and metastasis of prostate adenocarcinoma (PA-III) by ICRF 159. Prostate 1981; 2: 1-9.
12. Barker Grimshaw M, Davies RW, Hall WS. Combination therapy of a mouse sarcoma using razoxane and electron irradiation. Br J Cancer 1981; 44: 117-23.
13. Young SW, Hollenberg NK, Meinking TL et al. The influence of ICRF 159 on lymphatic and hematogenous metastases from rabbit V2 carcinoma. Unpublished report for USPHS Grants GM18674, GMO1910 and HL20895.
14. Gosalvez M, Blanco M, Hunter J et al. Effects of Anticancer agents on the respiration of isolated mitochondria and tumor cells. Eur J Cancer 1974; 10: 567-74.
15. Hallowes RC, West DG, Hellmann K. Cumulative cytostatic effect of ICRF 159. Nature 1974; 247: 487-90.
16. Sandberg J, Goldin A. Use of first generation transplants of a slow growing solid tumor for the evaluation of new cancer chemotherapeutic agents. Cancer Chemother Rep 1971; 55 1: 233-8.
17. Hellmann K, Tucker DF. Tumor growth in grids on chorio-allantoic membranes of chick embryos. Cancer Chemother Rep 1965; 47: 73-9.
18. Gitterman CO, Luell S. Chemotherapeutic studies on metastasis of human epidermoid carcinoma (H.Ep)#3 in the embryonated chick egg. In Garattini S, Franchi G (eds): Chemotherapy of Cancer Dissemination and Metastasis. New York: Raven Press 1973; 279-91.
19. Sharpe HBA, Field EO, Hellmann K. Mode of action of the cytostatic agent ICRF 159. Nature 1970; 226: 524-6.
20. Hellmann K, Williamson CJ, Sargent JM. Effect of Dexrazoxane on the cell cycle and intracellular ATP levels in K562 cells. Br Pharmacol Soc, Winter 2003 meeting; Abstract (in press).
21. O'Connell MJ, Begg CB, Silverstein MN et al. Randomized clinical trial comparing two dose regimens of ICRF 159 in refractory malignant lymphoma. Cancer Treat Rep 1980; 64: 1355-8.
22. Flannery EP, Corder MP, Sheehan WW et al. Phase II study of ICRF 159 in non-Hodgkin's lymphomas. Cancer Treat Rep 1978; 62: 465-7.
23. Gilbert JM, Hellmann K, Evans M et al. Randomized trial of oral adjuvant razoxane (ICRF 159) in resectable colorectal cancer: Five year follow-up. Br J Surg 1986; 73: 446-50.
24. Hellmann K, Gilbert J, Evans M et al. Effect of razoxane on metastases from colorectal cancer. Clin Exp Metastasis 1987; 5: 3-8.
25. Taylor RH, Gilbert JM, Evans M et al. Prospective serial liver ultrasound scanning in resectable colorectal cancer treated with adjuvant razoxane. Clin Exp Metastasis 1984; 2: 321-31.
26. Atherton DJ, Wells RS, Hellmann K. Razoxane (ICRF 159) in psoriasis. Lancet 1976; ii: 1296.
27. Horton JJ, Wells RS. Razoxane: A review of 6 years' therapy in psoriasis. Br J Dermatol 1983; 109: 669-73.
28. Mom A, Aresca S, Fuente G et al. Razoxane in the treatment of Psoriatic Patients resistant to or intolerant of PUVA, methotrexate and etretinate. Acta Dermatovener 1982; 62: 357-8.
29. Olweny CLM, Sikyewunda W, Otim D. Further experience with razoxane in treating Kaposi's sarcoma. Oncology 1980; 37: 174-6.
30. Kingston RD, Hellmann K. Razoxane for Crohn's colitis and non-specific proctitis. Br J Clin Pract 1993; 46: 252-5.
31. Braybrooke JP, O'Byme KJ, Propper DJ et al. A Phase II Study of Razoxane, an antiangiogenic topoisomerase II inhibitor in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin Cancer Res 2000; 6: 4697-704.
32. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nature Rev Cancer 2002; 2: 795-803.
33. Kingston RD, Fielding JWL, Palmer MK. An evaluation of the effectiveness and safety of razoxane when used as an adjunct to surgery in colorectal cancer. Int J Colorect Dis 1993; 8: 106-10.
34. Atherton A. The effect of ICRF 159 on liver metastases from a hamster lymphoma. Eur J Cancer 1975; 11: 383-8.
35. Peters LJ. A study of the influence of various diagnostic and therapeutic procedures applied to a murine squamous carcinoma on its metastatic behaviour. Br J Cancer 1975; 32: 355-65.
36. Hellmann K, Hutchinson GE. Unpublished report.
37. Gilbert JM, Thompson EM, Slavin et al. Inhibition of experimental colorectal cancer by razoxane (ICRF 159). Br J Surg 1984; 71: 600-3.
38. Baker D, Constable W, Elkon D. The influence of ICRF 159 and levamisole on the incidence of metastases following local irradiation of a solid tumor. Cancer 1981; 48: 2179-83.
39. Pimm MV, Baldwin RW. Influence of ICRF 159 and Triton WR 1339 on metastases of a rat epithelioma. Br J Cancer 1975; 31: 62-7.
40. Klenner T, Wingen F, Keppler B et al. Effects on tumour inhibition and survival time of a combination therapy of razoxane (ICRF 159) and two new cytostatica-linked biphosphonates in a transplantable rat osteosarcoma. Clin Exp Metastasis 1988; 6 (Suppl 1): 94.
41. Hellmann K, Rhomberg W. Radiotherapeutic enhancement by razoxane. Cancer Treat Rev 1991; 18: 225-40.
42. Herman EH, Mhatre RM, Lee IP et al. Prevention of the cardiotoxic effects of adriamycin and daunomycin in the isolated dog heart. Proc Soc Exp Biol Med 1972; 140: 234-9.
43. Swain SM, Whaley FS, Gerber MC et al. Delayed administration of Dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin containing therapy. J Clin Oncol 1997; 15: 1333-40.
44. Bakowski MT. ICRF 159 (±) 1,2-bis(3,5-dioxopiperazine-1-yl) propane, NSC-129, 943; razoxane. Cancer Treat Rev 1976; 3: 95-107.
45. Hasinoff BB, Hellmann K, Herman EH. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 1998; 5: 1-28.